{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:05:04Z","timestamp":1785902704928,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F32CA268527"],"award-info":[{"award-number":["F32CA268527"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2 TR002554"],"award-info":[{"award-number":["KL2 TR002554"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R38AI140297"],"award-info":[{"award-number":["1R38AI140297"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1245\/s10434-023-13567-4","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T18:02:52Z","timestamp":1684173772000},"page":"4813-4821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers"],"prefix":"10.1245","volume":"30","author":[{"given":"Kristen E.","family":"Rhodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bartholomew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Uronis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Strickler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Zani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Nussbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Lidsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"13567_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755\u201362. https:\/\/doi.org\/10.1097\/01.sla.0000251366.62632.d3.","journal-title":"Ann Surg."},{"key":"13567_CR2","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1200\/jco.2014.59.7591","volume":"33","author":"E Chan","year":"2015","unstructured":"Chan E, Berlin J. Biliary tract cancers: understudied and poorly understood. J Clin Oncol. 2015;33:1845\u20138. https:\/\/doi.org\/10.1200\/jco.2014.59.7591.","journal-title":"J Clin Oncol."},{"key":"13567_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin."},{"key":"13567_CR4","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/jco.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934\u201340. https:\/\/doi.org\/10.1200\/jco.2011.40.5381.","journal-title":"J Clin Oncol."},{"key":"13567_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192\u2013202. https:\/\/doi.org\/10.1002\/bjs.10776.","journal-title":"Br J Surg."},{"key":"13567_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/jco.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37:658\u201367. https:\/\/doi.org\/10.1200\/jco.18.00050.","journal-title":"J Clin Oncol."},{"key":"13567_CR7","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/jco.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40:2048\u201357. https:\/\/doi.org\/10.1200\/jco.21.02568.","journal-title":"J Clin Oncol."},{"issue":"15 Suppl","key":"13567_CR8","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1200\/JCO.2017.35.15_suppl.4006","volume":"35","author":"JN Primrose","year":"2017","unstructured":"Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol. 2017;35(15 Suppl):4006\u20134006. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.4006.","journal-title":"J Clin Oncol."},{"key":"13567_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/s1470-2045(18)30915-x","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663\u201373. https:\/\/doi.org\/10.1016\/s1470-2045(18)30915-x.","journal-title":"Lancet Oncol."},{"key":"13567_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/jco.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1015\u201327. https:\/\/doi.org\/10.1200\/jco.18.02178.","journal-title":"J Clin Oncol."},{"key":"13567_CR11","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Published 2022. Updated 15 July 2022. Retrieved 10 September 2022 at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf."},{"key":"13567_CR12","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/cancers13071647","volume":"13","author":"C Yoo","year":"2021","unstructured":"Yoo C, Shin SH, Park JO, et al. Current status and future perspectives of perioperative therapy for resectable biliary tract cancer: a multidisciplinary review. Cancers. 2021;13:1647. https:\/\/doi.org\/10.3390\/cancers13071647.","journal-title":"Cancers."},{"key":"13567_CR13","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3:1722\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905.","journal-title":"JAMA Oncol."},{"key":"13567_CR14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/jso.21173","volume":"99","author":"MV Raval","year":"2009","unstructured":"Raval MV, Bilimoria KY, Stewart AK, et al. Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol. 2009;99:488\u201390. https:\/\/doi.org\/10.1002\/jso.21173.","journal-title":"J Surg Oncol."},{"key":"13567_CR15","doi-asserted-by":"publisher","first-page":"djw324","DOI":"10.1093\/jnci\/djw324","volume":"109","author":"T Mitin","year":"2017","unstructured":"Mitin T, Enestvedt CK, Jemal A, et al. Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival. JNCI J Natl Cancer Inst. 2017;109:djw324. https:\/\/doi.org\/10.1093\/jnci\/djw324.","journal-title":"JNCI J Natl Cancer Inst."},{"key":"13567_CR16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","volume":"104","author":"ZS Morris","year":"2011","unstructured":"Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104:510\u201320. https:\/\/doi.org\/10.1258\/jrsm.2011.110180.","journal-title":"J R Soc Med."},{"key":"13567_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2016.08.013","volume":"107","author":"DP Sohal","year":"2016","unstructured":"Sohal DP, Shrotriya S, Abazeed M, et al. Molecular characteristics of biliary tract cancer. Crit Rev Oncol Hematol. 2016;107:111\u20138. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.013.","journal-title":"Crit Rev Oncol Hematol."},{"key":"13567_CR18","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.Cd-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7:1116\u201335. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0368.","journal-title":"Cancer Discov."},{"key":"13567_CR19","doi-asserted-by":"publisher","first-page":"14744","DOI":"10.18632\/oncotarget.4539","volume":"6","author":"G Brandi","year":"2015","unstructured":"Brandi G, Farioli A, Astolfi A, et al. Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget. 2015;6:14744\u201353. https:\/\/doi.org\/10.18632\/oncotarget.4539.","journal-title":"Oncotarget."},{"key":"13567_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21037\/tgh.2018.07.02","volume":"3","author":"A Pellino","year":"2018","unstructured":"Pellino A, Loupakis F, Cadamuro M, et al. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol. 2018;3:40. https:\/\/doi.org\/10.21037\/tgh.2018.07.02.","journal-title":"Transl Gastroenterol Hepatol."},{"key":"13567_CR21","doi-asserted-by":"publisher","first-page":"e051421","DOI":"10.1136\/bmjopen-2021-051421","volume":"12","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhang B, Liu C, et al. Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis. BMJ Open. 2022;12:e051421. https:\/\/doi.org\/10.1136\/bmjopen-2021-051421.","journal-title":"BMJ Open."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13567-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13567-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13567-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T20:27:59Z","timestamp":1688502479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13567-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["13567"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13567-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"2 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Rhodin is supported by NIH 1R38AI140297. A. Liu is supported by NIH F32CA268527. K. Rhodin and A. Liu both acknowledge support from the Duke Cancer Institute as part of the P30 Cancer Center Support Grant (grant ID: P30 CA014236). M. Lidsky receives funding support from the Department of Surgery and Duke Cancer Institute, the Duke School of Medicine Strong Start Award, The American College of Surgeons National Surgeon Scientist Program, and the Cholangiocarcinoma Foundation Research Fellowship Award. This project also was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant KL2 TR002554 (M. Lidsky). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. J. Strickler declares Abbvie: consulting (self); research grant (institution). Amgen: consulting (self); research grant (institution). AstraZeneca: consulting (self); research grant (institution). Beigene: consulting (self); research grant (institution). Daiichi-Sankyo: consulting (self); research grant (institution). Eli Lilly: consulting (self); research grant (institution). GSK: consulting (self); research grant (institution). Natera: consulting (self). Pfizer: consulting (self). Roche\/Genentech: consulting (self); research grant (institution). Seagen: consulting (self); research grant (institution). Takeda: consulting (self). Viatris: consulting (self). Silverback Therapeutics: consulting (self); research grant (institution). Astar D3: research grant (institution). Bayer: consulting (self); research grant (institution). Curegenix: research grant (institution). Gossamer Bio: research grant (institution). Leap Therapeutics: research grant (institution). Nektar: research grant (institution). Sanofi: research grant (institution).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}